Covid 19 situation and IP related brand equity on drugs

Agenda

12th December 2021

Covid 19 situation and IP related brand equity on drugs

The United States caught the world by surprise on 5 May 2021 when it announced its intention to support a World Trade Organization proposal that would temporarily waive intellectual property rights on covid-19 vaccines. While this move is encouraging, the Biden administration’s support is the first step of many required.

The IP rights waiver is essential to cover the global requirement of vaccines especially for the emerging as well as low income group countries. By April’ 2021, although 1.3 billion doses have been administered, however the same still constitutes of a meager 0.2% to these countries.

 

The hot topic on this issue is –

  • Analyzing the opportunities of ‘Open COVID Pledge’.

  • Licensing realms of Covid 19 by different Governments.

  • Bridging the gap between the inventors and investors and balancing the two sides.

  • Understanding the TRIPS agreement.